Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4123,223 shs237,144 shs
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
$3.28
$2.33
$60.00
$7.34M1.28212,944 shs56,500 shs
23andMe Holding Co. stock logo
ME
23andMe
$0.50
-35.3%
$0.50
$0.53
$10.81
$13.36M1.191.49 million shs29.28 million shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.40
+0.7%
$1.43
$0.94
$2.55
$22.50M0.88238,501 shs172,867 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+8.57%+55.56%
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.00%0.00%0.00%0.00%0.00%
23andMe Holding Co. stock logo
ME
23andMe
0.00%0.00%0.00%0.00%-94.16%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+0.72%-0.71%-9.74%+26.36%-20.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3412 of 5 stars
0.00.00.04.20.60.80.0
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
1.1018 of 5 stars
0.05.00.00.03.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.00
N/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
1.00
SellN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/A$6.54 per shareN/A
23andMe Holding Co. stock logo
ME
23andMe
$208.78M0.06$0.54 per share0.93$2.34 per share0.21
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
-$15.80MN/A0.00N/AN/AN/A-102.83%-22.74%N/A
23andMe Holding Co. stock logo
ME
23andMe
-$666.70M-$15.45N/AN/A-183.39%-170.07%-62.13%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.40
1.21
1.58
23andMe Holding Co. stock logo
ME
23andMe
N/A
1.05
0.91
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47

Institutional Ownership

CompanyInstitutional Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
12.30%
23andMe Holding Co. stock logo
ME
23andMe
36.10%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%

Insider Ownership

CompanyInsider Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.49%
23andMe Holding Co. stock logo
ME
23andMe
26.32%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
92.48 million2.46 millionNot Optionable
23andMe Holding Co. stock logo
ME
23andMe
77026.83 million19.77 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable

Recent News About These Companies

NanoViricides Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

First Wave BioPharma stock logo

First Wave BioPharma NASDAQ:FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

23andMe stock logo

23andMe NASDAQ:ME

$0.50 -0.27 (-35.32%)
Closing price 03/28/2025
Extended Trading
$0.50 0.00 (0.00%)
As of 03/28/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.40 +0.01 (+0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 -0.01 (-1.07%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.